Xcout Intel
Neumora competitors & alternatives
The 12 closest competitors and alternatives to Neumora among biotech companies — ranked by similarity to what Neumora actually does, not by market-cap band.
Subscribe to see Neumora’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Neumora
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Neumora at a glance
Neumora is a biotech company headquartered in United States. Xcout tracks 17 named people at Neumora, including Joshua Pinto (President and CEO). Xcout recorded 1 job posting from Neumora in the last 90 days.
Neumora leadership
- Joshua PintoPresident and CEO
- Michael MilliganChief Financial Officer
- Amy SullivanChief Human Resources Officer
- Bill AuroraChief Operating & Development Officer
- Jason DuncanChief Legal & Administrative Officer
- Nick BrandonChief Scientific Officer
11 more named people on record for Neumora, with roles, board committees and tenure — see the full roster →
Hiring at Neumora
Xcout recorded 1 job posting from Neumora in the last 90 days, from a hiring record Xcout has kept since August 2026.
The weekly hiring trend, the roles and locations behind it — see Neumora's hiring signals →
Top 12 Neumora competitors
Ranked by semantic similarity — how close each company is to Neumora by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Similar biotech company
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Similar biotech company
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Biotechnology
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Biotechnology
Navion Neurosciences, Inc. is a preclinical-stage biotechnology company located in Charlottesville, Virginia, that is developing next-generation, AI-enabled therapies.
Biotechnology
Nido Biosciences, Inc. is a clinical-stage holding and biotechnology company headquartered in Watertown, Massachusetts. The company focuses on discovering and advancing treatments for debilitating neurological diseases, including the development of targeted drugs.
Similar biotech company
Mirador Therapeutics, Inc. is a clinical-stage precision medicine company headquartered in San Diego, California, focused on developing first- and best-in-class next-generation therapeutics.
Similar biotech company
Elkedonia is a biotechnology company committed to introducing a pioneering, first-in-class antidepressant treatment utilizing precision medicine. Headquartered in Strasbourg, France, the company brings together stakeholders across the European ecosystem to advance innovative therapeutics.
Biotechnology
Tyra Biosciences is a biotechnology company headquartered in Carlsbad, California, that develops next-generation precision medicines.
Biotechnology
Aspen Neuroscience, Inc. is a clinical-stage private biotechnology company headquartered in San Diego, California. The company focuses on developing personalized autologous cell therapies for neurodegenerative diseases.
Similar biotech company
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Neumora and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Neumoraand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →